ForteBio

What ForteBio does

ForteBio is a life sciences instrumentation company specializing in label-free, real-time detection of molecular interactions. Its core product line is the Octet platform, a family of biolayer interferometry (BLI) instruments that measure binding kinetics, affinity, and protein-protein interactions without fluorescent or radioactive labels and that can operate on crude samples. The technology is positioned for protein quantification, characterization, antibody screening, and kinetic analysis in drug discovery and bioprocess development workflows. ForteBio also offers higher-throughput configurations of the Octet platform (e.g., the Octet R8e) and complementary Surface Plasmon Resonance (SPR) instruments, allowing it to address the full label-free interaction-analysis workflow from early-stage research through development-stage validation.

ForteBio operates as a wholly-owned subsidiary of Sartorius AG, the German bioprocessing and life sciences group, following Sartorius's acquisition in 2018. The subsidiary structure channels Octet-branded instruments, consumables, and related services through Sartorius's global direct sales force, online shop (shop.sartorius.com), and distributor network, with a separately incorporated Chinese entity (Sartorius ForteBio (Shanghai) Co., Ltd.) supporting the China market. Headcount is estimated at 501-1,000 across firmographic records, though no ForteBio-specific employee count is disclosed and this figure is likely blended with broader Sartorius ForteBio allocation; the consolidated Sartorius group reports approximately 14,000 employees and ~3.5 billion EUR in 2025 revenue. The customer base is concentrated in life sciences research and biopharmaceutical enterprises using label-free detection for protein interaction analysis, antibody characterization, and drug discovery applications.

The business model is a classic instrumentation razor-and-blade construct: instruments are placed with biopharmaceutical and academic customers, and recurring revenue comes from the consumables (sensor tips, assay kits, microplates) required to run each measurement cycle. Pricing is quote-based and not publicly disclosed, consistent with enterprise life sciences sales. Distribution is primarily B2B direct sales into pharma, biotech, and academic research institutions, augmented by Sartorius's trade-show participation and scientific publication resources (e.g., a published compendium on BLI and SPR assays). The company does not have a consumer-facing application, developer API, or SDK product, and its product launch cadence in 2025 is concentrated in the parent Sartorius portfolio (Biobrain Operate MES, Cubis III balances, Freiburg cell and gene therapy competence center) rather than in Octet-specific line extensions.

Name

ForteBio

Legal name

Sartorius ForteBio (Shanghai) Co., Ltd.

Website

https://sartorius.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

501–1,000 employees

Short description

ForteBio develops Octet biolayer interferometry (BLI) instruments and consumables for label-free, real-time protein interaction and kinetics analysis, serving life sciences research and biopharmaceutical customers. The company operates as a wholly-owned subsidiary of Sartorius AG.

Ownership category

akta.pro rank

Product category

Analytical Laboratory Instruments

NAICS

Analytical Laboratory Instrument Manufacturing (334516)

SIC

Laboratory Analytical Instruments (3826)

akta.pro primary industry

Mass Spectrometry & Spectroscopy Instruments (HLAGAIAB)

akta.pro secondary industry

Material Characterization & Spectroscopy (NMR/FTIR/MS) (HLAGADAK)

Keywords

• Biolayer interferometry systems
• Label-free detection
• Protein interaction analysis
• Biopharmaceutical instrumentation
• Binding kinetics measurement

Headquarters

HQ city

Menlo Park

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure

Distribution channels3 records

Marketing channels3 records

Core offering

ForteBio develops and manufactures the Octet biolayer interferometry (BLI) platform, a family of label-free analytical instruments that measure molecular interactions in real time. The instruments enable protein-protein interaction analysis, binding kinetics determination, antibody characterization, and drug discovery screening without requiring fluorescent or radioactive labels, including high-throughput configurations such as the Octet R8e.

Product overview

Sartorius offers a broad portfolio of biopharmaceutical manufacturing and laboratory equipment. The company operates a platform-plus-modules architecture with core product lines including biolayer interferometry (Octet), bioreactors, cell culture media, process chromatography, and filtration systems. The portfolio also includes laboratory instruments such as balances (Cubis III), pipettes (Picus 2), and water purification systems. For analytics, Sartorius provides high-throughput cytometry (iQue), live-cell imaging (Incucyte), and process analytical technology solutions. The company serves biopharmaceutical customers across the drug development lifecycle from discovery through manufacturing.

Differentiator

Problem solved

Functional benefit

Brands

• Octet: Biolayer interferometry instruments and consumables for protein analysis, quantification, and characterization used in biopharmaceutical development and life science research.

Products and services

• Octet BLI (Biolayer Interferometry) Systems

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Sartorius AGcoreStrategic or Co-development PartnerForteBio operates as a wholly-owned subsidiary of Sartorius AG. The company develops and manufactures the Octet biolayer interferometry platform for label-free, real-time detection of molecular interactions. Sartorius provides global distribution, manufacturing scale, and integration into its broader bioprocessing and life sciences portfolio.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Cytiva: Cytiva (formerly GE Healthcare Life Sciences) sells the Biacore SPR platform, the leading label-free surface plasmon resonance system for protein-protein interaction kinetics. Cytiva is ForteBio's closest direct competitor in label-free molecular interaction analysis for biopharma and life sciences.
• Molecular Devices: Molecular Devices (a Danaher operating company) supplies microplate readers, washers, and label-free analytical platforms used in drug discovery and biopharma QC, overlapping with ForteBio's kinetic and binding characterization use cases.
• Carterra: Carterra provides the LSA high-throughput SPR instrument for antibody kinetics and epitope mapping. It directly competes with ForteBio's high-throughput Octet configurations in antibody discovery and characterization workflows.

Broad incumbents

• Agilent Technologies: Agilent is a broad analytical instrument and life sciences solutions provider with mass spectrometry, chromatography, and cell analysis portfolios that compete in biopharma characterization, overlapping with ForteBio's analytical instrumentation footprint.
• Waters Corporation: Waters provides LC, MS, and informatics solutions used in biopharmaceutical characterization and quality control, addressing protein analytics workflows that overlap with ForteBio's customer base.
• Thermo Fisher Scientific: Thermo Fisher offers a comprehensive biopharma analytics and instrumentation portfolio (mass spec, chromatography, microplate readers) that intersects with ForteBio's protein characterization applications in discovery and QC.
• Bruker: Bruker manufactures high-end analytical instruments including mass spectrometers and biophysical tools used for protein characterization, overlapping with ForteBio's biomolecular interaction analysis market.
• PerkinElmer / Revvity: Revvity (formerly PerkinElmer's life sciences business) provides analytical and detection instruments used in biopharma and life sciences research, with overlapping reach into protein analysis and biophysical characterization.

Emerging players

• Malvern Panalytical: Malvern Panalytical provides light-scattering, imaging, and rheology instruments for biomolecular characterization, addressing complementary analytical workflows for biopharma development alongside ForteBio's BLI/SPR.
• Bio-Techne: Bio-Techne supplies proteins, antibodies, ELISA kits, and analytical reagents for life science research, often paired with ForteBio's instrumentation. It is an adjacent rather than direct competitor but operates in the same customer workflows.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/fortebio
• Facebookfacebook.com/fortebio
• LinkedInlinkedin.com/company/fortebio

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds2 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ForteBio